Skip to content

Comparison of the efficacy between Bofutsushosan and Daisaikoto in sleep apnea patients complicated with persistent obese and hypertension

Comparison of the efficacy between Bofutsushosan and Daisaikoto in sleep apnea patients complicated with persistent obese and hypertension - The efficacy of Japanese herbal medicines in sleep apnea patients complicated with persistent obese and hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003981
Enrollment
152
Registered
2010-08-15
Start date
2010-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea syndrome, Hypertension, Obesity

Interventions

Bofutsushosan 7.5g per day for 6months. Daisaikoto 7.5g per day for 6months. control(when the patients refused to take the medication)

Sponsors

Kyoto University,Graduate School of Medicine,Department of respiratory medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Persistent obesity and hypertension despite of 6 months of continuous positive airway pressure(CPAP) treatment for obstructive sleep apnea(OSA). 2.Obesity is defined as body mass index(BMI)>= 25kg/m2. 3.Hypertension is defined as systolic blood pressure(BP)>=130mmHg or diastolic BP>=80mmHg in more than twice determination. 4.OSA is defined as 1)sleepiness, apnea hypopnea index (AHI)>=5 and more than half of apnea is obstructive 2)AHI>=15 with or without OSA related symptoms. AHI is determined with polysomnography. 5.Undergoing appropriate nutrition and exercise therapy. 6.Patients using oral appliance will not be randomized. They will be instructed to start Bofutsushosan only.

Exclusion criteria

Exclusion criteria: 1.Acute infectious diseases or malignant diseases 2.New onset of cerebrovascular infarctions or myocardial infarctions within 6 months 3.Interventions for coronary arteries within 6 months 4.Admission due to angina pectoris or heart diseases within 6 months 5.Severe heart failure (NYHA class 3 or 4) or severe arrythmia 6.Systolic BP>=160mmHg or Diastolic BP >=100mg. (We should try other usual antihypertensive drugs rather than chinese herbal medicines) 7.Allergic for Bofutsushosan or Daisaikoto 8.Taking other herbal medicines 9.Severe liver failiure or renal failure(including patiens undergoing dailysis) 9.Interstitial pneumonitis 10.Undergoing interferon treatment for hepatitis 11.Pregnancy 12.Judged as inappropriate by attending physicians

Design outcomes

Primary

MeasureTime frame
Change in body weight

Secondary

MeasureTime frame
Blood pressure,Visceral fat accumulation

Countries

Japan

Contacts

Public ContactToru Oga

Graduate School of Medicine, Kyoto University Department of Respiratory Care and Sleep Control Medicine

075-751-3852

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026